Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients

Annals of the Rheumatic Diseases

Volumn 65, Issue 6, 2006, Pages 728-735

  Cutolo, Maurizio ^a   Capellino, S ^a   Montagna, P ^a   Sulli, A ^a   Seriolo, B ^a   Villaggio, B ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; MESSENGER RNA; METHOTREXATE; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MACROPHAGE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; T LYMPHOCYTE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; COCULTURE TECHNIQUES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; ISOXAZOLES; JURKAT CELLS; MACROPHAGES; MEMBRANE PROTEINS; METHOTREXATE; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL MEMBRANE; T-LYMPHOCYTES;

EID: 33744486051     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.045641     Document Type: Article

References (35)

1. Hitchon CA, el-Gabalawy HS. The histopathology of early synovitis. Clin Exp Rheumatol 2003;21:S28-36.
2. Ospelt C, Neidhart M, Gay RE, Gay S. Synovial activation in rheumatoid arthritis. Front Biosci 2004;9:2323-34.
3. Fairbanks LD, Bofil M, Ruckerman K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. J Biol Chem 1995;49:253-79.
4. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996;35:1270-3.
5. Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 2004;50(3):794-804.
6. Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M. Active leflunomide metabolite inhibits interleukin 1 beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 2003;62(5):440-3.
7. Burger D, Begue-Pastor N, Benavent S, Gruaz L, Kaufmann MT, Chicheportiche R, et al. The active metabolite of leflunomide, LEF-M, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 2003;42(1):89-96.
8. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000;165(10):5962-9.
9. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59(11):841-9.
10. Cutolo M, Sulli A, Ghiorzo P, Pizzorni C, Craviotto C, Villaggio B. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis 2003;62(4):297-302.
11. Grisar J, Arinqer M, Koller MD, Stummvoll GH, Eselbock D, Zwolfer B, et al. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 2004;63(12):1632-7.
12. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137(9):726-33.
13. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004;31(8):1521-31.
14. Van Riel P. Leflunomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate. Clin Exp Rheumatol 2003;21(6):695-6.
15. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60(8):729-35.
16. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23(4):739-5.
17. Cutolo M, Sulli A, Craviotto C, Felli L, Pizzorni C, Seriolo B, et al. Antiproliferative-antiinflammatory effects of methotrexate and sex hormones on cultured differentiating myeloid monocytic cells (THP-1). Ann N Y Acad Sci 2002;966:232-7.
18. Cutolo M, Bisso A, Sulli A, Felli L, Briata M, Pizzorni C, et al. Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol 2000;27(11):2551-7.
19. Ho CY, Wong CK, Li EK, Tam LS, Lam CW. Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. Clin Exp Immunol 2003;133(1):132-8.
20. Bacher S, Schmitz ML. The NF-kappaB pathway as a potential target for autoimmune disease therapy. Curr Pharm Des 2004;10(23):2827-37.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-2.
22. Kremer JM. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999;29(1):14-26.
23. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42(7):1322-8.
24. Kraan MC, Reece RJ, Barg EC, Smeets TJM, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2000;4:1820-30.
25. Elder RT, Xu X, Gong H, Finnegan A, Chong ASF. The immunosuppressive metabolite of leflunomide, A771726, affects murine T cells through two biochemical mechanisms. J Immunol 1997;159:22-7.
26. Dimitrijevic M, Bartlett RR. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant Proc 1996;28:3086.
27. Recee RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 2002;46:366-72.
28. Smith MD, Kraan MC, Slavotinek J, Au V, Weedon H, Parker A, et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatology (Oxford) 2001;40:367-74.
29. Halminton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol 1999;127:1589-96.
30. Weithmann KU, Jeske S, Schlotte V. Effects of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation. Agents Actions 1994;41(3-4):164-70.
31. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A771726) blocks TNF-dependent nuclear factor-kB activation and gene expression. J Immunol 1999;162:2095.
32. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular response: effects on NF-kB, activator protein-1, c-Jun, N-terminal protein kinase and apoptosis. J Immunol 2000;165:5962-9.
33. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibition. J Biol Chem 1995;270:29682-9.
34. Kalden JR, Smolen JS, Emery P, van Riel PL, Dougados M, Strand CV, et al. Lefunomide in combination therapy. J Rheumatol Suppl 2004;71:25-30.
35. Dayer JM, Cutolo M. Is there a rationale to using leflunomide in early rheumatoid arthritis? Clin Exp Rheumatol 2005;23:404-12.